NGeneBio Co Ltd - ESG Rating & Company Profile powered by AI
The SDG assessment for NGeneBio Co Ltd indicates its reporting of the United Nations Sustainable Development Goals. Comprehensive ESG analysis of NGeneBio Co Ltd can be accessed by registering for free. This page contains a zero-cost ESG report for NGeneBio Co Ltd.
NGeneBio Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.6; made up of an environmental score of 0.0, social score of 4.8 and governance score of 0.0.
1.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1682 | Viracta Therapeutics Inc | 1.7 | Low |
| 1682 | Werewolf Therapeutics Inc | 1.7 | Low |
| 1715 | NGeneBio Co Ltd | 1.6 | Low |
| 1715 | CareDx Inc | 1.6 | Low |
| 1715 | Catalyst Biosciences Inc | 1.6 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does NGeneBio Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes NGeneBio Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes NGeneBio Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes NGeneBio Co Ltd offer flexible work?
Sign up for free to unlockDoes NGeneBio Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes NGeneBio Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes NGeneBio Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose water use targets?
Sign up for free to unlockDoes NGeneBio Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid NGeneBio Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes NGeneBio Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas NGeneBio Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes NGeneBio Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes NGeneBio Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs NGeneBio Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose its waste policy?
Sign up for free to unlockDoes NGeneBio Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose energy use targets?
Sign up for free to unlockDoes NGeneBio Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes NGeneBio Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for NGeneBio Co Ltd
These potential risks are based on the size, segment and geographies of the company.
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing; and OncoaccuPanel, a solid tumor oncology next generation sequencing test. The company also provides NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS. In addition, it offers IDaccuTest, a short tandem repeat test for family relationship testing, identity testing, forensics, and chimerism analysis; and NGenePlex nCoV qRT-PCR Kit, a reagent of real-time reverse transcription-polymerase chain reaction assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19. The company was founded in 2015 and is headquartered in Seoul, South Korea.